Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
- Market Cap ₹ 223 Cr.
- Current Price ₹ 63.2
- High / Low ₹ 87.5 / 31.9
- Stock P/E
- Book Value ₹ 16.8
- Dividend Yield 0.00 %
- ROCE -17.4 %
- ROE -16.3 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.76 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 5.14%
- Company has a low return on equity of -20.4% over last 3 years.
- Promoter holding has decreased over last 3 years: -15.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|
4 | 0 | 15 | 19 | 21 | |
4 | 10 | 28 | 32 | 36 | |
Operating Profit | 0 | -10 | -13 | -13 | -15 |
OPM % | 3% | -87% | -66% | -69% | |
0 | 0 | 1 | 0 | 0 | |
Interest | 0 | 0 | 2 | 2 | 3 |
Depreciation | 0 | 0 | 2 | 2 | 2 |
Profit before tax | 0 | -10 | -16 | -17 | -20 |
Tax % | 0% | -24% | -24% | -22% | |
0 | -8 | -12 | -14 | -16 | |
EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.70 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 70% |
TTM: | 102% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -33% |
Stock Price CAGR | |
---|---|
10 Years: | 31% |
5 Years: | 82% |
3 Years: | 71% |
1 Year: | 46% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -20% |
Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 10 | 21 | 35 | 35 |
Reserves | -2 | 1 | 37 | 24 |
0 | 0 | 9 | 39 | |
2 | 2 | 11 | 22 | |
Total Liabilities | 11 | 25 | 91 | 120 |
0 | 0 | 63 | 77 | |
CWIP | 0 | 2 | 7 | 5 |
Investments | 0 | 3 | 0 | 0 |
11 | 19 | 21 | 39 | |
Total Assets | 11 | 25 | 91 | 120 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
-0 | -4 | -11 | -14 | |
0 | -5 | -75 | -12 | |
0 | 21 | 78 | 23 | |
Net Cash Flow | 0 | 12 | -8 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 124 | 65 | 59 | |
Inventory Days | 91 | 0 | 114 | 347 |
Days Payable | 236 | 163 | 465 | |
Cash Conversion Cycle | -21 | 16 | -59 | |
Working Capital Days | -18 | -69 | -160 | |
ROCE % | -64% | -28% | -17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Newspaper publication of Unaudited Financial Results (Consolidated and standalone) for the quarter ended 30th June 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
7 Aug - CEO Dr. S Prasad resigns; three senior management appointments effective August 7, 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
7 Aug - CEO Dr. S Prasad resigns effective August 7, 2025, citing personal reasons.
- Unaudited Financial Results For The Quarter Ended June 30, 2025. 7 Aug
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated August 07, 2025.
7 Aug - Q1 results approved; CEO resigned; three senior management appointed effective Aug 7, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint